- Wondering whether IDEXX Laboratories at around US$577 per share is priced for perfection or still leaves room on the table, this article focuses squarely on what that current price might imply about value.
- The stock has had a mixed stretch recently, with a 3.7% gain over the last 7 days, a 5.1% decline over the past 30 days, and a 13.8% decline year to date, while still showing a 52.4% return over the last year and 21.0% and 14.0% annualized over 3 and 5 years.
- Recent price moves are occurring against an evergreen backdrop, where investors are revisiting long term compounders and reassessing what they are prepared to pay for quality healthcare names. For IDEXX, this means current valuations are being weighed more carefully against business fundamentals rather than short term headlines.
- On Simply Wall St’s 6 point valuation framework, IDEXX scores 1 out of 6. Next up is a look at how traditional methods like P/E comparisons and discounted cash flow line up with that score, and then an alternative way to think about valuation that can give you a more complete picture by the end of the article.
IDEXX Laboratories scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: IDEXX Laboratories Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and discounting them back to today, so everything is expressed in present value terms.
For IDEXX Laboratories, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.03b. Analyst and extrapolated estimates from Simply Wall St project free cash flow reaching $1.90b in 2030, with intermediate years such as 2026 and 2027 at $1.11b and $1.29b respectively, all in $ and expressed in present value through discounting.
Adding these discounted cash flows and a terminal value together gives an estimated intrinsic value of about $513.35 per share. Against a recent share price around $577, the DCF output points to the stock trading at roughly a 12.5% premium to this model’s estimate, which counts as overvalued on this framework.
Result: OVERVALUED
Our Discounted Cash Flow (DCF) analysis suggests IDEXX Laboratories may be overvalued by 12.5%. Discover 62 high quality undervalued stocks or create your own screener to find better value opportunities.
Approach 2: IDEXX Laboratories Price vs Earnings
For a profitable company like IDEXX Laboratories, the P/E ratio is a useful way to gauge what investors are currently willing to pay for each dollar of earnings. A higher P/E often reflects higher growth expectations or a perception of lower risk, while a lower P/E can reflect more modest growth assumptions or higher perceived risk.
IDEXX trades on a P/E of 43.40x, compared with a Medical Equipment industry average of about 26.73x and a peer group average of 26.67x. On these simple comparisons, the stock sits well above both its industry and peers. However, Simply Wall St’s “Fair Ratio” framework estimates a P/E of 28.27x as a more appropriate level, based on factors such as IDEXX’s earnings growth profile, profit margins, industry, market capitalization and company specific risks.
This Fair Ratio is designed to be more tailored than a basic peer or industry comparison because it adjusts for differences in growth, risk and profitability, rather than assuming all Medical Equipment companies should trade on similar multiples. Comparing IDEXX’s current 43.40x P/E to the Fair Ratio of 28.27x suggests the shares are trading above what this framework would consider justified by fundamentals.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your IDEXX Laboratories Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Simply Wall St’s Narratives let you attach a clear story to your numbers by linking your view of IDEXX Laboratories to a specific forecast for revenue, earnings, margins and an implied fair value, all inside the Community page used by millions of investors. This way, you can quickly compare that fair value to the current price when deciding whether to act, see your view update automatically as fresh news or earnings arrive, and understand why one investor might see IDEXX as closer to the more cautious US$470 bear case while another leans toward the optimistic US$785 scenario, based on different assumptions about factors like Cancer Dx adoption, recurring diagnostics, international growth and future P/E multiples.
For IDEXX Laboratories however we will make it really easy for you with previews of two leading IDEXX Laboratories Narratives:
Here is the bullish case that leans toward a higher fair value and assumes the company can keep compounding its diagnostics and software strengths.
🐂 IDEXX Laboratories Bull Case
Fair value in this bull narrative: about US$750.23 per share.
Current price vs this fair value: roughly 23.0% below the narrative fair value.
Revenue growth used in this narrative: 9.01% a year.
- Assumes recurring diagnostics and cloud software keep expanding, supported by product adoption and strong customer retention across clinics.
- Builds in revenue growth of about 9% a year and a higher profit margin over time, with analysts using a discount rate of 7.69% to bring those future earnings back to today.
- Anchors on an analyst consensus price target of about US$695, framed by a bullish US$785 upper end and a US$420 lower end, with the average view that the stock is close to fairly priced against those assumptions.
Now here is the more cautious narrative, which still assumes growth but is more restrained about how much investors might want to pay for it.
🐻 IDEXX Laboratories Bear Case
Fair value in this bear narrative: about US$555.82 per share.
Current price vs this fair value: roughly 3.9% above the narrative fair value.
Revenue growth used in this narrative: 8.65% a year.
- Focuses on pressures from softer clinic visit volumes, potential pet ownership headwinds, and competition that could limit pricing power and recurring consumables growth.
- Uses slightly lower revenue growth than the bullish view and assumes a future P/E of about 37x on 2029 earnings, discounted back at 7.71% to reach a fair value near US$556.
- Aligns with the lower end of analyst targets, where the bearish price target sits only slightly below the recent share price, implying these analysts see IDEXX as broadly fairly priced with tighter room for error.
If you want to see how your own view of IDEXX Laboratories stacks up against these storylines and numbers, you can step through the full community range of Narratives and stress test the assumptions that matter most to you. See what the community is saying about IDEXX Laboratories.
Do you think there's more to the story for IDEXX Laboratories? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com